A Phase 1/2 interventional study of TNP-2092 capsules and Placebo in Hyperammonemia, sponsored by TenNor Therapeutics (Suzhou) Limited. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-25.
Sponsored by TenNor Therapeutics (Suzhou) Limited · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this study was to evaluate the safety, tolerability, and pharmacokinetic characteristics of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia; and to preliminarily observe the effects of the study drug on blood ammonia and hepatic encephalopathy related clinical symptoms and signs, neuropsychological indicators, and quality of life in liver cirrhosis patients with hyperammonemia.
The aim of this study was to evaluate the safety, tolerability, and pharmacokinetic characteristics of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia; and to preliminarily observe the effects of the study drug on blood ammonia and hepatic encephalopathy related clinical symptoms and signs, neuropsychological indicators, and quality of life in liver cirrhosis patients with hyperammonemia.
A total of 3 dose groups will be set up, i.e., 100 mg BID, 300 mg BID and 600 mg BID groups. Drugs will be orally administered 30 min after breakfast and dinner for 14 consecutive days, and last dose will be administered 30 min after breakfast on the morning of D15. Each dose group will include a study drug TNP-2092 capsule arm and a placebo control arm. Subjects will exit upon completion of the safety and tolerability evaluation on D17.
Twelve liver cirrhosis patients with hyperammonemia are planned to be enrolled in each dose group. The 12 patients will be assigned in a ratio of 2:1 to the TNP-2092 capsule arm and the placebo arm, with 8 patients receiving TNP-2092 Capsules and 4 receiving placebos.
Enrollment for the second dose group may start only after the previous dose group has fully completed the treatment period and passed the safety and tolerability evaluation.
25 studies on the registry are indexed under Hyperammonemia; 3 are open to participants now.
This study's enrollment of 36 is above the median of 31 across 16 interventional studies indexed under Hyperammonemia.
Browse Hyperammonemia studies →TenNor Therapeutics (Suzhou) Limited is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received TNP-2092 capsules orally twice daily at the dose of 100 mg in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15.
Drug: TNP-2092 capsules
Subjects received TNP-2092 capsules orally twice daily at the dose of 300 mg in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15.
Drug: TNP-2092 capsules
Subjects received TNP-2092 capsules orally twice daily at the dose of 600 mg in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15.
Drug: TNP-2092 capsules
Subjects received TNP-2092 placebo capsules orally twice daily in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15.
Drug: Placebo
Administration orally.
Also known as: Rifaquizinone capsules
Administration orally.
Also known as: TNP-2092 placebo capsules
Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs)
To investigate the safety and tolerability of TNP-2092 by assessment of the number of participants with AEs following administration of TNP-2092 capsules. An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
Time frame: Up to 17 days after the first dosing.
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia on Day 1.
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose
Area Under the Plasma Concentration-time Curve From the Time of Administration to the Time of the Last Measurable Plasma Concentration (AUC0-last) on Day 1.
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose
Area Under the Plasma Concentration-time Curve From the Time of Administration Extrapolated to Infinity (AUC0-∞) on Day 15
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose
Time to Reach the Maximum Observed Plasma Concentration (Tmax) on Day 1
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia on Day 15.
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose
Area Under the Plasma Concentration-time Curve From the Time of Administration to the Time of the Last Measurable Plasma Concentration (AUC0-last) on Day 15.
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose
Time to Reach the Maximum Observed Plasma Concentration (Tmax) Day 15
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose
Area Under the Plasma Concentration-time Curve From the Time of Administration Extrapolated to Infinity (AUC0-∞) Day 1
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose
Half Life (t1/2) of TNP-2092 Capsules on Day 1
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose
Half Life (t1/2) of TNP-2092 Capsules on Day 15
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose
Area Under the Plasma Concentration-time Curve Within a Dosing Interval (AUC0-tau) on Day 1
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 1: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h and 12 h post-dose
Area Under the Plasma Concentration-time Curve Within a Dosing Interval (AUC0-tau) on Day 15
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
Time frame: Day 15: 30-60 min prior to the first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose
Accumulation Index Rac(Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Rac (Cmax) was calculated from the ratio of Cmax (Day 15) to Cmax (Day 1)
Time frame: Day 1: 30-60 min prior to first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, and 12 h post-dose (prior to next dose). Day 15: 30-60 min pre-dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose.
Accumulation Index Rac(AUC) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Rac (AUC) was calculated from the ratio of AUC0-tau (Day 15) to AUC0-tau(Day 1).
Time frame: Day 1: 30-60 min prior to first dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, and 12 h post-dose (prior to next dose). Day 15: 30-60 min pre-dose, and 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h and 36 h post-dose.
Changes in the Fasting Venous Blood Ammonia Concentration From Baseline (Mean Pre-treatment Measured)
The changes in the fasting venous blood ammonia concentration from baseline will be compared with the placebo to evaluate the preliminary efficacy of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia.
Time frame: Baseline and Day 15
Proportion of Participants With Positive Result of Number Connection Test A (NCT-A)
Evaluation of NCT-A is based on the time required to complete the test. The results will be positive according to following criteria: 1) the time is over 34.3 seconds while the age is less than 35 years; 2) the time is over 45.7 seconds while the age is between 35 to 44 years; 3) the time is over 52.8 seconds while age is between 45 to 54 years; 4) the time is over 61.9 seconds while the age is between 55 to 64 years. The positive result means a worse outcome.
Time frame: Baseline, Day 7 and Day 15
Proportion of Participants With Positive Result of Digital Symbol Test (DST)
Evaluation of Digital symbol test (DST) is based on the score gained within 90 seconds, and the results are positive according to following criteria: 1) the score is less than 40.5 while the age is less than 35 years; 2) the score is less than 35.0 while the age is between 35 to 44 years; 3) the score is less than 28.5 while the age is between 45 to 54 years; 4) the score is less than 26.0 while the age is between 55 to 64 years. The positive result means a worse outcome.
Time frame: Baseline, Day 7 and Day 15
Changes in the Total Scores of Quality of Life (QOL) From Baseline
Changes in the total scores of QOL from baseline will be compared with the placebo to evaluate the preliminary efficacy of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia. The range of QOL scores is 30 \~ 150. Patients with lower scores means a better outcome.
Time frame: Baseline, Day 7 and Day 15
Proportion of Participants Whose Asterixis is Elicited
Asterixis is a physical exam finding that can be elicited by asking the participant to extend the arms, flex the wrists, and spread the fingers wide. Clinically, asterixis produces flapping tremors. In a flapping tremor, an participant will flap their wrists like a bird flapping its wings. Asterixis elicited means a worse outcome.
Time frame: Baseline, Day 7 and Day 15
Clinical Grade of Hepatic Encephalopathy
Grade 0 of HE (without HE) is nomal, Grade 0 of HE (MHE) is alterations of brain function in neuropsychological or neurophysiological measures without clinical signs of HE, Grade 1 of HE is mild lack of awareness, Grade 2 of HE is lethargic, Grade 3 of HE is somnolent, and Grade 4 of HE is coma. Higher score means worse outcome.
Time frame: Baseline, Day 7 and Day 15
Areas Under the Blood Ammonia Concentration-time Curve
Plasma concentrations of Blood Ammonia were measured by a specific and validated assay. Changes in the Fasting Venous Blood Ammonia Concentration From Baseline were used to measure AUC.
Time frame: Baseline to Day 15
| Milestone | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID | TNP-2092 Capsules Placebo |
|---|---|---|---|---|
| Started | 8 | 8 | 8 | 12 |
| Completed | 7 | 8 | 8 | 11 |
| Not completed | 1 | 0 | 0 | 1 |
To investigate the safety and tolerability of TNP-2092 by assessment of the number of participants with AEs following administration of TNP-2092 capsules. An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
| participants | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID | Placebo |
|---|---|---|---|---|
| Safety of TNP-2092 by Assessment of the Number of Participants With Adverse Events (AEs) | 6 | 6 | 7 | 8 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| ng/ml | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia on Day 1. | 90.4 ± 42.9 | 140 ± 120 | 415 ± 294 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h*ng/ml | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From the Time of Administration to the Time of the Last Measurable Plasma Concentration (AUC0-last) on Day 1. | 309 ± 178 | 524 ± 537 | 1610 ± 1200 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h*ng/ml | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From the Time of Administration Extrapolated to Infinity (AUC0-∞) on Day 15 | 396 ± 257 | 756 ± 570 | 2680 ± 1790 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID |
|---|---|---|---|
| Time to Reach the Maximum Observed Plasma Concentration (Tmax) on Day 1 | 4.75 ± 0.46 | 5.13 ± 0.36 | 5.13 ± 0.35 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| ng/ml | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia on Day 15. | 60.8 ± 28.5 | 164 ± 118 | 543 ± 420 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h*ng/ml | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From the Time of Administration to the Time of the Last Measurable Plasma Concentration (AUC0-last) on Day 15. | 380 ± 247 | 739 ± 555 | 2610 ± 1730 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID |
|---|---|---|---|
| Time to Reach the Maximum Observed Plasma Concentration (Tmax) Day 15 | 4.43 ± 0.78 | 4.75 ± 0.46 | 4.50 ± 1.85 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h*ng/ml | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From the Time of Administration Extrapolated to Infinity (AUC0-∞) Day 1 | 332 ± 188 | 561 ± 565 | 1790 ± 1210 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID |
|---|---|---|---|
| Half Life (t1/2) of TNP-2092 Capsules on Day 1 | 2.52 ± 0.63 | 2.23 ± 0.81 | 2.99 ± 2.29 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID |
|---|---|---|---|
| Half Life (t1/2) of TNP-2092 Capsules on Day 15 | 8.17 ± 1.84 | 6.92 ± 2.63 | 7.93 ± 1.09 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h*ng/mL | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve Within a Dosing Interval (AUC0-tau) on Day 1 | 309 ± 179 | 525 ± 538 | 1610 ± 1200 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.
| h*ng/mL | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve Within a Dosing Interval (AUC0-tau) on Day 15 | 303 ± 187 | 646 ± 466 | 2230 ± 1480 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Rac (Cmax) was calculated from the ratio of Cmax (Day 15) to Cmax (Day 1)
| ratio | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID |
|---|---|---|---|
| Accumulation Index Rac(Cmax) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia | 0.74 ± 0.22 | 1.23 ± 0.49 | 1.26 ± 0.42 |
Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Rac (AUC) was calculated from the ratio of AUC0-tau (Day 15) to AUC0-tau(Day 1).
| ratio | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID |
|---|---|---|---|
| Accumulation Index Rac(AUC) of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia | 1.09 ± 0.40 | 1.38 ± 0.39 | 1.47 ± 0.55 |
The changes in the fasting venous blood ammonia concentration from baseline will be compared with the placebo to evaluate the preliminary efficacy of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia.
| μmol/L | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID | Placebo |
|---|---|---|---|---|
| Changes in the Fasting Venous Blood Ammonia Concentration From Baseline (Mean Pre-treatment Measured) | 5.7 ± 17.50 | -2.1 ± 22.49 | -14.1 ± 18.12 | 0.5 ± 45.29 |
Evaluation of NCT-A is based on the time required to complete the test. The results will be positive according to following criteria: 1) the time is over 34.3 seconds while the age is less than 35 years; 2) the time is over 45.7 seconds while the age is between 35 to 44 years; 3) the time is over 52.8 seconds while age is between 45 to 54 years; 4) the time is over 61.9 seconds while the age is between 55 to 64 years. The positive result means a worse outcome.
| Participants | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID | Placebo |
|---|---|---|---|---|
| Baseline | 6 | 6 | 8 | 12 |
| Day 7 | 7 | 6 | 8 | 12 |
| Day 15 | 5 | 7 | 8 | 11 |
Evaluation of Digital symbol test (DST) is based on the score gained within 90 seconds, and the results are positive according to following criteria: 1) the score is less than 40.5 while the age is less than 35 years; 2) the score is less than 35.0 while the age is between 35 to 44 years; 3) the score is less than 28.5 while the age is between 45 to 54 years; 4) the score is less than 26.0 while the age is between 55 to 64 years. The positive result means a worse outcome.
| Participants | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID | Placebo |
|---|---|---|---|---|
| Baseline | 4 | 2 | 3 | 7 |
| Day 7 | 4 | 2 | 3 | 8 |
| Day 15 | 0 | 1 | 3 | 7 |
Changes in the total scores of QOL from baseline will be compared with the placebo to evaluate the preliminary efficacy of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia. The range of QOL scores is 30 \~ 150. Patients with lower scores means a better outcome.
| score on a scale | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID | Placebo |
|---|---|---|---|---|
| Day 7 | -6.1 ± 5.64 | 6.4 ± 15.80 | 3.1 ± 13.91 | 0.5 ± 9.21 |
| Day 15 | -3.0 ± 4.73 | 7.1 ± 15.82 | 4.6 ± 5.63 | -1.4 ± 15.88 |
Asterixis is a physical exam finding that can be elicited by asking the participant to extend the arms, flex the wrists, and spread the fingers wide. Clinically, asterixis produces flapping tremors. In a flapping tremor, an participant will flap their wrists like a bird flapping its wings. Asterixis elicited means a worse outcome.
| Participants | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID | Placebo |
|---|---|---|---|---|
| Whether asterixis is elicited at Baseline — Yes | 0 | 0 | 0 | 0 |
| Whether asterixis is elicited at Baseline — No | 8 | 8 | 8 | 12 |
| Whether asterixis is elicited on Day 7 — Yes | 0 | 0 | 0 | 0 |
| Whether asterixis is elicited on Day 7 — No | 8 | 8 | 8 | 12 |
| Whether asterixis is elicited on Day 15 — Yes | 0 | 0 | 0 | 0 |
| Whether asterixis is elicited on Day 15 — No | 8 | 8 | 8 | 12 |
Grade 0 of HE (without HE) is nomal, Grade 0 of HE (MHE) is alterations of brain function in neuropsychological or neurophysiological measures without clinical signs of HE, Grade 1 of HE is mild lack of awareness, Grade 2 of HE is lethargic, Grade 3 of HE is somnolent, and Grade 4 of HE is coma. Higher score means worse outcome.
| Participants | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID | Placebo |
|---|---|---|---|---|
| Baseline — Grade 0 of HE (without HE) | 2 | 2 | 0 | 0 |
| Baseline — Grade 0 of HE (MHE) | 6 | 6 | 8 | 12 |
| Baseline — Grade 1 of HE | 0 | 0 | 0 | 0 |
| Baseline — Grade 2 of HE | 0 | 0 | 0 | 0 |
| Baseline — Grade 3 of HE | 0 | 0 | 0 | 0 |
| Baseline — Grade 4 of HE | 0 | 0 | 0 | 0 |
| Day 7 — Grade 0 of HE (without HE) | 1 | 1 | 0 | 0 |
| Day 7 — Grade 0 of HE (MHE) | 7 | 7 | 8 | 12 |
| Day 7 — Grade 1 of HE | 0 | 0 | 0 | 0 |
| Day 7 — Grade 2 of HE | 0 | 0 | 0 | 0 |
| Day 7 — Grade 3 of HE | 0 | 0 | 0 | 0 |
| Day 7 — Grade 4 of HE | 0 | 0 | 0 | 0 |
| Day 15 — Grade 0 of HE (without HE) | 1 | 1 | 0 | 0 |
| Day 15 — Grade 0 of HE (MHE) | 7 | 7 | 8 | 12 |
| Day 15 — Grade 1 of HE | 0 | 0 | 0 | 0 |
| Day 15 — Grade 2 of HE | 0 | 0 | 0 | 0 |
| Day 15 — Grade 3 of HE | 0 | 0 | 0 | 0 |
| Day 15 — Grade 4 of HE | 0 | 0 | 0 | 0 |
Plasma concentrations of Blood Ammonia were measured by a specific and validated assay. Changes in the Fasting Venous Blood Ammonia Concentration From Baseline were used to measure AUC.
| h*μmol/L | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID | Placebo |
|---|---|---|---|---|
| Day 1 | 481.6 ± 564.5 | 480.2 ± 607.9 | 225.0 ± 544.1 | 85.5 ± 999.3 |
| Day 1-Day 15 | -1716.7 ± 5778.5 | -3205.4 ± 8311.8 | -5805.6 ± 6080.5 | -5476.3 ± 12816.5 |
Collected over 17 days after the first dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TNP-2092 Capsules 100mg Twice Daily(BID) | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| TNP-2092 Capsules 300mg BID | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| TNP-2092 Capsules 600mg BID | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Placebo | 0/12 (0%) | 1/12 (8.3%) | 8/12 (66.7%) |
| Event | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID | Placebo |
|---|---|---|---|---|
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/8 | 0/8 | 0/8 | 1/12 |
| Event | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID | Placebo |
|---|---|---|---|---|
| neutrophil count decreasedInvestigations | 2/8 | 4/8 | 6/8 | 6/12 |
| white blood cell count decreasedInvestigations | 2/8 | 2/8 | 6/8 | 4/12 |
| Lymphocyte count decreasedInvestigations | 1/8 | 2/8 | 4/8 | 2/12 |
| Platelet count decreasedInvestigations | 3/8 | 1/8 | 0/8 | 5/12 |
| Lipase increasedInvestigations | 3/8 | 0/8 | 0/8 | 0/12 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 2/8 | 2/8 | 1/8 | 2/12 |
| Alanine aminotransferase increasedInvestigations | 0/8 | 2/8 | 0/8 | 0/12 |
| Aspartate aminotransferase increasedInvestigations | 0/8 | 2/8 | 0/8 | 0/12 |
| Blood fibrinogen decreasedInvestigations | 2/8 | 0/8 | 0/8 | 1/12 |
| AnaemiaBlood and lymphatic system disorders | 1/8 | 1/8 | 0/8 | 2/12 |
| Age, Categorical(Participants) | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID | TNP-2092 Capsules Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 8 | 8 | 12 | 36 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID | TNP-2092 Capsules Placebo | Total |
|---|---|---|---|---|---|
| Mean | 49.5 ± 7.19 | 50.4 ± 5.71 | 51.9 ± 7.97 | 52.3 ± 10.15 | 51.1 ± 8.0 |
| Sex: Female, Male(Participants) | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID | TNP-2092 Capsules Placebo | Total |
|---|---|---|---|---|---|
| Female | 0 | 1 | 3 | 4 | 8 |
| Male | 8 | 7 | 5 | 8 | 28 |
| Race (NIH/OMB)(Participants) | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID | TNP-2092 Capsules Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 8 | 8 | 8 | 12 | 36 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Fasting Venous Blood Ammonia Concentration(μmol/L) | TNP-2092 Capsules 100mg Twice Daily(BID) | TNP-2092 Capsules 300mg BID | TNP-2092 Capsules 600mg BID | TNP-2092 Capsules Placebo | Total |
|---|---|---|---|---|---|
| Mean | 90.1 ± 27.1 | 80.3 ± 19.5 | 78.8 ± 17.3 | 115.8 ± 39.1 | 94.0 ± 32.0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2020 to primary completion in Jun 2021, 9 months.
Results were first posted in May 2024, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TNP-2092
TenNor Therapeutics (Suzhou) Limited